ZA201105164B - Anti-cmet antibody - Google Patents

Anti-cmet antibody

Info

Publication number
ZA201105164B
ZA201105164B ZA2011/05164A ZA201105164A ZA201105164B ZA 201105164 B ZA201105164 B ZA 201105164B ZA 2011/05164 A ZA2011/05164 A ZA 2011/05164A ZA 201105164 A ZA201105164 A ZA 201105164A ZA 201105164 B ZA201105164 B ZA 201105164B
Authority
ZA
South Africa
Prior art keywords
cmet antibody
cmet
antibody
Prior art date
Application number
ZA2011/05164A
Other languages
English (en)
Inventor
Liliane Goetsch
Thierry Wurch
Cedric Bes
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41693124&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201105164(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/IB2008/055663 external-priority patent/WO2010064089A1/en
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of ZA201105164B publication Critical patent/ZA201105164B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Connection Of Motors, Electrical Generators, Mechanical Devices, And The Like (AREA)
ZA2011/05164A 2008-12-02 2011-07-13 Anti-cmet antibody ZA201105164B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/IB2008/055663 WO2010064089A1 (en) 2008-12-02 2008-12-02 Novel anti-cmet antibody
US18450209P 2009-06-05 2009-06-05
PCT/EP2009/066201 WO2010069765A1 (en) 2008-12-02 2009-12-02 ANTI-cMET ANTIBODY

Publications (1)

Publication Number Publication Date
ZA201105164B true ZA201105164B (en) 2012-03-28

Family

ID=41693124

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2011/05164A ZA201105164B (en) 2008-12-02 2011-07-13 Anti-cmet antibody

Country Status (38)

Country Link
US (4) US8741290B2 (cg-RX-API-DMAC10.html)
EP (4) EP2370468B1 (cg-RX-API-DMAC10.html)
JP (3) JP5863458B2 (cg-RX-API-DMAC10.html)
KR (1) KR101838299B1 (cg-RX-API-DMAC10.html)
CN (2) CN103351438B (cg-RX-API-DMAC10.html)
AR (1) AR074439A1 (cg-RX-API-DMAC10.html)
AU (3) AU2009328318C1 (cg-RX-API-DMAC10.html)
BR (2) BR122019023930B1 (cg-RX-API-DMAC10.html)
CA (1) CA2743433C (cg-RX-API-DMAC10.html)
CL (2) CL2011001296A1 (cg-RX-API-DMAC10.html)
CO (1) CO6382139A2 (cg-RX-API-DMAC10.html)
CR (1) CR20110324A (cg-RX-API-DMAC10.html)
CY (2) CY1119172T1 (cg-RX-API-DMAC10.html)
DK (2) DK3135691T3 (cg-RX-API-DMAC10.html)
EC (1) ECSP11011127A (cg-RX-API-DMAC10.html)
ES (3) ES2697098T3 (cg-RX-API-DMAC10.html)
GE (2) GEP20135930B (cg-RX-API-DMAC10.html)
HR (2) HRP20171011T8 (cg-RX-API-DMAC10.html)
HU (3) HUE051288T2 (cg-RX-API-DMAC10.html)
IL (2) IL213273A0 (cg-RX-API-DMAC10.html)
LT (2) LT2370468T (cg-RX-API-DMAC10.html)
MA (1) MA32892B1 (cg-RX-API-DMAC10.html)
MX (2) MX2011005677A (cg-RX-API-DMAC10.html)
MY (2) MY192567A (cg-RX-API-DMAC10.html)
NZ (1) NZ593853A (cg-RX-API-DMAC10.html)
PE (1) PE20120343A1 (cg-RX-API-DMAC10.html)
PH (1) PH12015501515A1 (cg-RX-API-DMAC10.html)
PL (3) PL3431502T3 (cg-RX-API-DMAC10.html)
PT (3) PT2370468T (cg-RX-API-DMAC10.html)
RS (2) RS56204B1 (cg-RX-API-DMAC10.html)
RU (2) RU2560257C2 (cg-RX-API-DMAC10.html)
SA (2) SA112331005B1 (cg-RX-API-DMAC10.html)
SG (2) SG171851A1 (cg-RX-API-DMAC10.html)
SI (3) SI3135691T1 (cg-RX-API-DMAC10.html)
TN (1) TN2011000216A1 (cg-RX-API-DMAC10.html)
TW (2) TWI523866B (cg-RX-API-DMAC10.html)
WO (1) WO2010069765A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201105164B (cg-RX-API-DMAC10.html)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2014681A1 (en) 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
US8545839B2 (en) * 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
EP2287197A1 (en) * 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET antibody and its use for the detection and the diagnosis of cancer
EP3904391B1 (en) 2010-03-10 2024-07-10 Genmab A/S Monoclonal antibodies against c-met
KR20140019284A (ko) 2010-09-03 2014-02-14 아카데미아 시니카 항-C-Met 항체 및 이의 이용 방법들
EP3165538A1 (en) 2010-11-03 2017-05-10 Argen-X Nv Anti c-met antibodies
JP6400470B2 (ja) 2011-05-16 2018-10-03 ジェネロン（シャンハイ）コーポレイション リミテッド 多重特異性Ｆａｂ融合タンパク質および使用法
KR101865223B1 (ko) 2011-10-05 2018-06-08 삼성전자주식회사 항 ｃ-Ｍｅｔ 인간화 항체 및 그의 용도
KR20130036993A (ko) * 2011-10-05 2013-04-15 삼성전자주식회사 ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체
EP2773660A2 (en) 2011-11-03 2014-09-10 Argen-X B.V. Chimeric human-camel antigens and their use
KR101463098B1 (ko) * 2011-11-28 2014-11-27 한국생명공학연구원 ｃ-Ｍｅｔ에 대한 인간항체에 약물이 접합된 약물 복합체 및 이의 용도
US8900582B2 (en) 2011-12-22 2014-12-02 Samsung Electronics Co., Ltd. Deimmunized anti c-Met humanized antibodies and uses thereof
HK1208181A1 (en) * 2012-06-21 2016-02-26 Sorrento Therapeutics, Inc. Antigen binding proteins that bind c-met
EP2708556B1 (en) 2012-09-12 2018-11-07 Samsung Electronics Co., Ltd Pharmaceutical composition for the use in a combination therapy for prevention or treatment of c-met or angiogenesis factor induced diseases
DK2839860T3 (da) 2012-10-12 2019-06-17 Medimmune Ltd Pyrrolobenzodiazepiner og konjugater deraf
ES2687439T3 (es) 2013-03-13 2018-10-25 Medimmune Limited Pirrolobenzodiazepinas y conjugados de las mismas
KR102049990B1 (ko) * 2013-03-28 2019-12-03 삼성전자주식회사 c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
EP2992019B1 (en) 2013-04-30 2019-03-06 Agency For Science, Technology And Research Mab 2 anti-met antibody
US9567641B2 (en) * 2013-07-03 2017-02-14 Samsung Electronics Co., Ltd. Combination therapy for the treatment of cancer using an anti-C-met antibody
US9717715B2 (en) 2013-11-15 2017-08-01 Samsung Electronics Co., Ltd. Method of combination therapy using an anti-C-Met antibody
EP3083697B1 (en) * 2013-12-20 2019-04-17 Development Center for Biotechnology Alpha-enolase specific antibodies and methods of uses in cancer therapy
EP3193940A1 (en) 2014-09-10 2017-07-26 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
KR20170136536A (ko) * 2015-03-16 2017-12-11 셀덱스 쎄라퓨틱스, 인크. 항-met 항체 및 그 사용 방법
EP3411067B1 (en) * 2016-02-05 2021-10-20 Helixmith Co., Ltd Anti-c-met antibodies and uses thereof
WO2017157305A1 (en) 2016-03-15 2017-09-21 Generon (Shanghai) Corporation Ltd. Multispecific fab fusion proteins and use thereof
RS61659B1 (sr) 2016-05-17 2021-04-29 Abbvie Biotherapeutics Inc Konjugati antitelo lek anti-cmet i metode za njihovu upotrebu
US10457726B2 (en) 2016-06-30 2019-10-29 University Of Connecticut Antibody and antigen-binding fragment compositions targeting cell surface antigens in tumors and methods of use thereof
CN109862919A (zh) 2016-10-11 2019-06-07 免疫医疗有限公司 抗体-药物缀合物联合免疫介导的治疗剂
WO2018088933A1 (en) * 2016-11-14 2018-05-17 Limited Liability Company "Panacela Labs" Anti-tumor effects of a viral vector encoding a toll-like receptor and a toll-like receptor agonist
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
TW201825515A (zh) * 2017-01-04 2018-07-16 美商伊繆諾金公司 Ｍｅｔ抗體以及其免疫結合物及用途
CN109771642B (zh) * 2017-11-13 2022-09-20 同济大学苏州研究院 c-MET激动型抗体及其用途
GB201803892D0 (en) 2018-03-12 2018-04-25 Ultrahuman Six Ltd C-met binding agents
CA3098103A1 (en) 2018-05-23 2019-11-28 Adc Therapeutics Sa Molecular adjuvant
CN113164570B (zh) * 2018-08-08 2024-05-14 蜻蜓疗法股份有限公司 结合nkg2d、cd16和肿瘤相关抗原的蛋白质
EP3847196A4 (en) 2018-09-07 2023-01-04 ITabMed (HK) Limited BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
CN109541221B (zh) * 2018-10-24 2022-03-22 益善生物技术股份有限公司 一种c-Met特异性抗体、组合物及试剂盒
KR102353568B1 (ko) * 2018-11-14 2022-01-20 주식회사 헬릭스미스 안정성이 향상된 항 c-Met 항체 또는 그의 항원 결합 단편
WO2020132810A1 (en) 2018-12-24 2020-07-02 Generon (Shanghai) Corporation Ltd. Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
WO2020198731A2 (en) * 2019-03-28 2020-10-01 Danisco Us Inc Engineered antibodies
CN114340684B (zh) 2019-09-16 2025-09-12 瑞泽恩制药公司 用于免疫pet成像的放射性标记的met结合蛋白
JP7510518B2 (ja) 2020-09-01 2024-07-03 レメゲン シーオー．，エルティーディー． 抗ｃ－Ｍｅｔ抗体薬物複合体及びその応用
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
EP4319811A1 (en) 2021-04-06 2024-02-14 Abbvie Biotherapeutics Inc. Methods of treatment of non-small-cell lung carcinoma using telisotuzumab vedotin
AU2022254291A1 (en) * 2021-04-08 2023-10-12 Byondis B.V. Anti-c-met antibodies and antibody-drug conjugates
AR125473A1 (es) * 2021-04-29 2023-07-19 Abbvie Inc Conjugados de anticuerpo anti-c-met y fármaco
CN117980327A (zh) 2021-11-03 2024-05-03 杭州多禧生物科技有限公司 抗体的特异性偶联
US20230285394A1 (en) 2022-03-11 2023-09-14 Abbvie Biotherapeutics Inc. Methods of treatment of non-small-cell lung carcinoma using telisotuzummab vedotin and osimertinib
AU2024276234A1 (en) 2023-05-23 2025-12-04 AbbVie Manufacturing Management Unlimited Company Methods of treatment using anti-c-met antibody drug conjugates
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2026098440A1 (zh) * 2024-11-05 2026-05-15 上海齐鲁制药研究中心有限公司 一种双特异性抗体偶联物及其制备方法和应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4424200A (en) 1979-05-14 1984-01-03 Nuc Med Inc. Method for radiolabeling proteins with technetium-99m
US4479930A (en) 1982-07-26 1984-10-30 Trustees Of The University Of Massachusetts Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8924581D0 (en) 1989-11-01 1989-12-20 Pa Consulting Services Bleaching of hair
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
CA2436326C (en) * 2001-01-09 2012-08-14 Merck Patent Gesellschaft Mit Beschraenkter Haftung Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
MXPA05008521A (es) * 2003-02-13 2005-10-20 Pharmacia Corp Anticuerpos a c-met para el tratamiento de canceres.
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
CN1922208A (zh) * 2003-12-11 2007-02-28 健泰科生物技术公司 用于抑制c－met二聚化及活化的方法和组合物
ME01803B (me) * 2004-08-05 2010-12-31 Genentech Inc Humanizovani anti-cmet antagonisti
CA2606102C (en) * 2005-04-26 2014-09-30 Medimmune, Inc. Modulation of antibody effector function by hinge domain engineering
DK1915398T3 (en) 2005-07-18 2016-07-04 Amgen Inc Humane anti-B7RP1 neutraliserende antistoffer
US8652469B2 (en) * 2005-07-28 2014-02-18 Novartis Ag M-CSF-specific monoclonal antibody and uses thereof
BRPI0709917A2 (pt) 2006-03-30 2011-07-05 Novartis Ag composições e métodos de uso para anticorpos de c-met
EP2014681A1 (en) * 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
US8545839B2 (en) 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody

Also Published As

Publication number Publication date
MX341014B (es) 2016-08-03
DK2370468T3 (en) 2017-06-19
US8747850B2 (en) 2014-06-10
ES2629855T3 (es) 2017-08-16
PT2370468T (pt) 2017-07-13
AU2017203929B2 (en) 2019-03-28
JP5863458B2 (ja) 2016-02-16
SA109300720B1 (ar) 2013-05-25
CN103351438A (zh) 2013-10-16
ES2827277T3 (es) 2021-05-20
SA112331005B1 (ar) 2015-09-13
EP3431502B1 (en) 2020-07-22
GEP20146207B (en) 2014-12-10
US20130109844A1 (en) 2013-05-02
JP2012510280A (ja) 2012-05-10
EP3431502A1 (en) 2019-01-23
CL2014000181A1 (es) 2014-07-25
AU2009328318C1 (en) 2017-11-02
MA32892B1 (fr) 2011-12-01
JP2017099392A (ja) 2017-06-08
LT3135691T (lt) 2018-11-12
CL2011001296A1 (es) 2011-08-26
GEP20135930B (en) 2013-10-10
PE20120343A1 (es) 2012-04-16
US8741290B2 (en) 2014-06-03
PH12015501515A1 (en) 2015-12-14
TW201446805A (zh) 2014-12-16
TWI523866B (zh) 2016-03-01
HK1162536A1 (zh) 2012-08-31
MY185200A (en) 2021-04-30
AU2009328318A1 (en) 2011-07-28
JP6309657B2 (ja) 2018-04-11
KR20110097839A (ko) 2011-08-31
WO2010069765A1 (en) 2010-06-24
MX2011005677A (es) 2011-06-30
ECSP11011127A (es) 2011-07-29
US8729249B2 (en) 2014-05-20
US20130109841A1 (en) 2013-05-02
TWI459964B (zh) 2014-11-11
TW201023892A (en) 2010-07-01
LT2370468T (lt) 2017-07-10
KR101838299B1 (ko) 2018-03-14
HUE035047T2 (en) 2018-05-02
AU2016200725A1 (en) 2016-02-25
HUE051288T2 (hu) 2021-03-01
SG171851A1 (en) 2011-07-28
AR074439A1 (es) 2011-01-19
HK1190414A1 (zh) 2014-07-04
IL231525B (en) 2019-07-31
PL3135691T3 (pl) 2019-02-28
NZ593853A (en) 2013-03-28
HRP20181868T1 (hr) 2019-01-11
JP6074018B2 (ja) 2017-02-01
HRP20171011T1 (hr) 2017-09-22
SI3431502T1 (sl) 2021-01-29
PT3431502T (pt) 2020-10-29
SI2370468T1 (sl) 2017-08-31
DK3135691T3 (en) 2018-11-19
CA2743433A1 (en) 2010-06-24
RS56204B1 (sr) 2017-11-30
PL2370468T3 (pl) 2017-09-29
HUE040553T2 (hu) 2019-03-28
PL3431502T3 (pl) 2020-12-28
CN103351438B (zh) 2016-04-20
BRPI0923231B1 (pt) 2020-04-28
AU2017203929A1 (en) 2017-07-06
CO6382139A2 (es) 2012-02-15
US20110239316A1 (en) 2011-09-29
MY192567A (en) 2022-08-29
BRPI0923231B8 (pt) 2021-05-25
RU2011124751A (ru) 2013-01-10
RU2015127471A (ru) 2018-12-21
EP3135691A1 (en) 2017-03-01
ES2697098T3 (es) 2019-01-22
CY1121025T1 (el) 2019-12-11
IL231525A0 (en) 2014-04-30
US8765128B2 (en) 2014-07-01
US20130109840A1 (en) 2013-05-02
RU2560257C2 (ru) 2015-08-20
SI3135691T1 (sl) 2018-12-31
JP2016117721A (ja) 2016-06-30
EP3757132A1 (en) 2020-12-30
CR20110324A (es) 2011-07-28
CN102227446A (zh) 2011-10-26
CY1119172T1 (el) 2018-02-14
BR122019023930B1 (pt) 2021-05-04
AU2016200725B2 (en) 2017-05-25
CN102227446B (zh) 2015-10-21
AU2016200725C1 (en) 2017-10-19
SG187518A1 (en) 2013-02-28
EP2370468A1 (en) 2011-10-05
EP2370468B1 (en) 2017-04-05
CA2743433C (en) 2019-06-11
RS58018B1 (sr) 2019-02-28
HRP20171011T8 (hr) 2019-01-25
IL213273A0 (en) 2011-07-31
TN2011000216A1 (en) 2012-12-17
EP3135691B1 (en) 2018-08-15
BRPI0923231A2 (pt) 2016-01-26
PT3135691T (pt) 2018-11-27
AU2009328318B2 (en) 2015-11-05

Similar Documents

Publication Publication Date Title
HRP20181868T1 (hr) Anti-cmet antitijelo
IL276622A (en) Antibody formulation
ZA201102119B (en) Improved antibody libraies
IL209142A0 (en) Anti-flt3 antibodies
GB0821100D0 (en) Antibodies
EP2077859A4 (en) ANTIBODY FORMULATION
PL2146745T3 (pl) Pięcioswoiste przeciwciało
SG2014011365A (en) Novel antibody formulation
EP2138576A4 (en) ANTI-CLAUDIN-4 ANTIBODY
ZA201006099B (en) Anti-tyrp1 antibodies
IL205073A0 (en) Anti-bst2 antibody
ZA201007976B (en) Anti-pirb antibodies
GB0818356D0 (en) Antibodies
GB0911770D0 (en) Antibody
GB0817621D0 (en) Antibody
GB0817622D0 (en) Antibody
GB0806230D0 (en) Antibodies
GB0823562D0 (en) Antibodies
GB0819113D0 (en) An antibody
GB0805901D0 (en) Auto-battery-system